Investigation Report on China Zoledronic Acid Market, 2010-2019
Description
Malignancy with bone metastases is common in patients with advanced tumor like breast cancer, lung cancer, prostate cancer and multiple myeloma. Since patients with breast cancer or prostate cancer have relatively long median survival time, they still face the problem of treating bone metastases. Meanwhile, patients with lung cancer also need to pay attention to bone metastases despite their short median survival due to lung cancer’s high incidence. The complications of bone metastases include bony pain, pathological fracture, spinal cord compression and hypercalcemia. The most common drug for bone metastases is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
Developed by Novartis, zoledronic acid first appeared in the market in Canada in Oct. 2000 and then in May, it entered Britain. In Aug. 2001, it was approved by FDA to be sold under the trade name of Zometa. As the new generation of diphosphonate, zoledronic acid can inhibit the activity of osteoclasts, slow down bone resorption and reduce the incidence of bone metastases in cancer patients. Compared with pamidronate, zoledronic acid is more effective in inhibiting hypercalcemia in patients with multiple myeloma or solid tumor, alleviating pain, delaying bone metastases and other complications.
Each year, the number of new cases of cancer in China reaches more than 3 million, among which about 50% is with bone metastases. Zoledronic acid develops fast after entering China, annual sales value rising from less than CNY 12 million in 2005 to CNY 474 million in 2014 and CAGR during this period reaching 52%. Novartis (Switzerland), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd occupy the majority of the market share, among which Novartis (Switzerland) has the largest market share of over 70% for sales value in 2014.
Readers can get at least the following information from this report:
Malignancy with bone metastases is common in patients with advanced tumor like breast cancer, lung cancer, prostate cancer and multiple myeloma. Since patients with breast cancer or prostate cancer have relatively long median survival time, they still face the problem of treating bone metastases. Meanwhile, patients with lung cancer also need to pay attention to bone metastases despite their short median survival due to lung cancer’s high incidence. The complications of bone metastases include bony pain, pathological fracture, spinal cord compression and hypercalcemia. The most common drug for bone metastases is diphosphonate. Three generations of diphosphonate, respectively, etidronate and clodronate representated by Bonefos, pamidronate and alendronate sodium represented by Bonin as well as sodium ibandronate and zoledronic acid are now used in the clinic.
Developed by Novartis, zoledronic acid first appeared in the market in Canada in Oct. 2000 and then in May, it entered Britain. In Aug. 2001, it was approved by FDA to be sold under the trade name of Zometa. As the new generation of diphosphonate, zoledronic acid can inhibit the activity of osteoclasts, slow down bone resorption and reduce the incidence of bone metastases in cancer patients. Compared with pamidronate, zoledronic acid is more effective in inhibiting hypercalcemia in patients with multiple myeloma or solid tumor, alleviating pain, delaying bone metastases and other complications.
Each year, the number of new cases of cancer in China reaches more than 3 million, among which about 50% is with bone metastases. Zoledronic acid develops fast after entering China, annual sales value rising from less than CNY 12 million in 2005 to CNY 474 million in 2014 and CAGR during this period reaching 52%. Novartis (Switzerland), Chia Tai Tianqing Pharmaceutical Group Co., Ltd, Jiangsu Hengrui Medicine Co., Ltd, Sichuan Hairong Pharmaceutical Co., Ltd and Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd occupy the majority of the market share, among which Novartis (Switzerland) has the largest market share of over 70% for sales value in 2014.
Readers can get at least the following information from this report:
- market size of zoledronic acid in China
- competitive landscape of zoledronic acid in Chinese market
- price of zoledronic acid made by different enterprises in China
- market outlook of zoledronic acid in China
- manufacturers of anti-tumor drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF ZOLEDRONIC ACID
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ZOLEDRONIC ACID IN CHINA
2.1 Patent and Approval Status of Zoledronic Acid in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ZOLEDRONIC ACID IN CHINESE HOSPITALS IN 2014
6.1 Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd (Trade Name: Zhuolai)
6.2 Sichuan Hairong Pharmaceutical Co., Ltd (Trade Name: Suqi)
6.3 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Ailang)
6.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Tianqing Yitai)
6.5 Novartis (Switzerland) (Trade Name: Zometa)
7 MAJOR MANUFACTURERS OF ZOLEDRONIC ACID IN CHINESE MARKET, 2010-2014
7.1 Novartis
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd
7.3 Jiangsu Hengrui Medicine Co., Ltd
7.4 Sichuan Hairong Pharmaceutical Co., Ltd
7.5 Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd
8 MARKET OUTLOOK OF ZOLEDRONIC ACID IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
Table of Charts
Chart Approval Information of Zoledronic Acid in China
Chart Sales Status of Zoledronic Acid in China
Chart Sales Value of Zoledronic Acid in China, 2010-2014 (unit in CNY million)
Chart Sales Value of Zoledronic Acid in Some Regions in China, 2010-2014 (unit in CNY million)
Chart Sales Volume of Zoledronic Acid in China, 2010-2014 (unit: million)
Chart Sales Volume of Zoledronic Acid in Some Regions in China, 2010-2014 (unit: thousand)
Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Other Enterprises in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Injection in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Injection in China, 2010-2014
Chart Price of Zoledronic Acid Made by Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Sichuan Hairong Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Novartis (Switzerland) in Some Chinese Cities in 2014
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF ZOLEDRONIC ACID IN CHINA
2.1 Patent and Approval Status of Zoledronic Acid in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF ZOLEDRONIC ACID IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF ZOLEDRONIC ACID IN CHINESE HOSPITALS IN 2014
6.1 Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd (Trade Name: Zhuolai)
6.2 Sichuan Hairong Pharmaceutical Co., Ltd (Trade Name: Suqi)
6.3 Jiangsu Hengrui Medicine Co., Ltd (Trade Name: Ailang)
6.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Tianqing Yitai)
6.5 Novartis (Switzerland) (Trade Name: Zometa)
7 MAJOR MANUFACTURERS OF ZOLEDRONIC ACID IN CHINESE MARKET, 2010-2014
7.1 Novartis
7.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd
7.3 Jiangsu Hengrui Medicine Co., Ltd
7.4 Sichuan Hairong Pharmaceutical Co., Ltd
7.5 Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd
8 MARKET OUTLOOK OF ZOLEDRONIC ACID IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape
Table of Charts
Chart Approval Information of Zoledronic Acid in China
Chart Sales Status of Zoledronic Acid in China
Chart Sales Value of Zoledronic Acid in China, 2010-2014 (unit in CNY million)
Chart Sales Value of Zoledronic Acid in Some Regions in China, 2010-2014 (unit in CNY million)
Chart Sales Volume of Zoledronic Acid in China, 2010-2014 (unit: million)
Chart Sales Volume of Zoledronic Acid in Some Regions in China, 2010-2014 (unit: thousand)
Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Made by Other Enterprises in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Zoledronic Acid for Sales Volume in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Novartis (Switzerland) in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Chia Tai Tianqing in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Made by Jiangsu Hengrui in China, 2010-2014
Chart Sales Value and Market Share of Zoledronic Acid Injection in China, 2010-2014
Chart Sales Volume and Market Share of Zoledronic Acid Injection in China, 2010-2014
Chart Price of Zoledronic Acid Made by Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Sichuan Hairong Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Jiangsu Hengrui Medicine Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
Chart Price of Zoledronic Acid Made by Novartis (Switzerland) in Some Chinese Cities in 2014
